Beyond traditional chemotherapy, antiangiogenic agents like bevacizumab, which inhibit tumor angiogenesis through vascular endothelial growth factor (VEGF) blockade, have shown benefits in prolonging progression-free survival (PFS) in advanced OC [14]. The gene discussed is VEGFA; the disease is neoplasm.